Why a 2020 spotlight will fall on tafasitamab
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The next orthopaedics megamerger
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Horizon looks for a new growth driver
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
GTX Medical gains a new technology and loses a competitor
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Why Novo Nordisk should buy Uniqure
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.